The Journal of Pediatrics
Volume 156, Issue 6 , Pages 953-959.e1 , June 2010

Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida

  • Christian Hampp, PhD

      Affiliations

    • Department Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL
    • Corresponding Author InformationReprint requests: Dr Christian Hampp, 101 Newell Drive, Room 3334, Gainesville, FL, 32610.
    • ,
  • Arwa S. Saidi, MBBCh

      Affiliations

    • Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL
    • ,
  • Almut G. Winterstein, PhD

      Affiliations

    • Department Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL
    • Department of Epidemiology and Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL

Received 13 July 2009 ,Revised 13 November 2009 ,Accepted 9 December 2009.

References 

  1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282:1440–1446
  2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588–598
  3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531–537
  4. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540
  5. Drug Topics Red Book . Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR. December 2006;
  6. Committee on Infectious Diseases and Committee on Fetus and Newborn . Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 Pt 1):1442–1446
  7. Brief report . respiratory syncytial virus activity–United States, July 2006-November 2007. MMWR. 2007;56:1263–1265
  8. Bauman J, Eggleston M, Oquist N, Malinoski F. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab. South Med J. 2007;100:669–676
  9. http://www.doh.state.fl.us/Disease_ctrl/epi/RSV/rsv_trends.htm. Accessed 07/09/2009.
  10. http://www.cdc.gov/surveillance/nrevss/rsv/default.html. Accessed 02/23/2009.
  11. Committee on Infectious Diseases and Committee on Fetus and Newborn . Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV. Pediatrics. 1998;102:1211–1216
  12. Mansbach J, Kunz S, Acholonu U, Clark S, Camargo CA. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr Emerg Care. 2007;23:362–367
  13. Moynihan JA, Kim TY, Young T, Checchia PA. Rate of palivizumab administration in accordance with current recommendations among hospitalized children. J Pediatr Health Care. 2004;18:224–227
  14. Pignotti MS, Catarzi S, Donzelli GA. 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved?. J Matern Fetal Neonatal Med. 2006;19:221–224
  15. Oh PI, Lanctjt KL, Yoon A, Lee DS, Paes BA, Simmons BS, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21:512–518
  16. Giusti R. North American synagis prophylaxis survey. Pediatr Pulmonol. 2009;44:96–98
  17. Respiratory Syncytial Virus. Red Book 2009;1:560–569.
  18. Bellavance M, Rohlicek CV, Bigras JL, Cote JM, Paquet M, Lebel MH, et al. Palivizumab use among children with congenital heart disease in Quebec: impact of Canadian guidelines on clinical practice. Paediatr Child Health. 2006;11:19–23
  19. Hampp C, Winterstein AG, Saidi A. Role of Age in Respiratory Syncytial Virus Infection Risk: Recommendations for Palivizumab Utilization, presented at 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Pharmacoepidemiol Drug Safety. 2008;17:186
  20. Jacobson Vann J, Feaganes J, Wegner S. Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab. Pharmacoeconomics. 2007;25:793–800

 Supported in part by a grant from the Florida Agency of Healthcare Administration, AHCA. The authors declare no conflicts of interest.

PII: S0022-3476(09)01245-1

doi: 10.1016/j.jpeds.2009.12.016

The Journal of Pediatrics
Volume 156, Issue 6 , Pages 953-959.e1 , June 2010

Article Tools

* Image Usage & Resolution